Roche Holding AG Neurology Update Virtual Event Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Emmanuel Papadakis - Deutsche Bank - Analyst : Thank you for taking the question, sir. Maybe one, Trontinemab. Can you just remind us your late -- in terms of next steps on the clinical development program, just remind us your latest thoughts on a fixed duration approach in the Phase 3 and where we are in terms of the Phase 3 initiation timelines and what that study might look like? And then maybe Prasinezumab, it sounds like you're continuing to see some opportunity for continued developing of a molecule despite two missed Phase 2 studies. So just give us your latest thoughts in terms of where you go from here and potential future further clinical development. Thank you. Luka Kulic - Roche Holding AG - Vice President, Global Head of Early Development, Neuroscience & Rare Diseases, Roche pRED I can maybe start with Trontinemab. So the plan is to initiate, as shared at ADPD, the Phase 3 study by the end of this year. Details on the design, duration, study population, et cetera, will be shared at upcoming conferences. So we cannot comment at this point in time on these details.

Question: Emmanuel Papadakis - Deutsche Bank - Analyst : Understood. I'll be patient. Thank you.

Question: Emmanuel Papadakis - Deutsche Bank - Analyst : All good. Thank you.